ATE256464T1 - Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole - Google Patents

Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole

Info

Publication number
ATE256464T1
ATE256464T1 AT96916817T AT96916817T ATE256464T1 AT E256464 T1 ATE256464 T1 AT E256464T1 AT 96916817 T AT96916817 T AT 96916817T AT 96916817 T AT96916817 T AT 96916817T AT E256464 T1 ATE256464 T1 AT E256464T1
Authority
AT
Austria
Prior art keywords
benzimidazoles
infectious diseases
controlling infectious
dicationic bis
dicationic
Prior art date
Application number
AT96916817T
Other languages
English (en)
Inventor
Christine C Dykstra
John R Perfect
David W Boykin
David W Wilson
Richard R Tidwell
Original Assignee
Univ North Carolina
Univ Duke
Univ Georgia State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Univ Duke, Univ Georgia State filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE256464T1 publication Critical patent/ATE256464T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96916817T 1995-06-07 1996-06-03 Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole ATE256464T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,996 US5643935A (en) 1995-06-07 1995-06-07 Method of combatting infectious diseases using dicationic bis-benzimidazoles
PCT/US1996/008084 WO1996040145A1 (en) 1995-06-07 1996-06-03 Methods of combatting infectious diseases using dicationic bis-benzimidazoles

Publications (1)

Publication Number Publication Date
ATE256464T1 true ATE256464T1 (de) 2004-01-15

Family

ID=23877744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916817T ATE256464T1 (de) 1995-06-07 1996-06-03 Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole

Country Status (9)

Country Link
US (11) US5643935A (de)
EP (1) EP0831832B1 (de)
JP (1) JPH11507036A (de)
AT (1) ATE256464T1 (de)
AU (1) AU705261B2 (de)
CA (1) CA2223912A1 (de)
DE (1) DE69631134T2 (de)
ES (1) ES2213775T3 (de)
WO (1) WO1996040145A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770617A (en) * 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US6635668B1 (en) * 1998-07-22 2003-10-21 The University Of North Carolina At Chapel Hill Imidazoline receptor binding compounds
CA2344445A1 (en) * 1998-09-17 2000-03-23 The University Of North Carolina At Chapel Hill Antifungal activity of dicationic molecules
EP1685836A3 (de) * 1998-09-17 2007-05-09 University Of North Carolina At Chapel Hill Antimykotische Wirkung von dikationischen Molekülen
EP1165096B1 (de) * 1999-03-29 2009-09-09 Shire Canada Inc. Verwendung von cytidinderivaten zur behandlung von leukämie
DK1231910T3 (da) * 1999-11-16 2009-08-31 Oncozyme Pharma Inc Pentamidin til behandling af cancer
US7115665B1 (en) 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
US7156809B2 (en) 1999-12-17 2007-01-02 Q-Tec Systems Llc Method and apparatus for health and disease management combining patient data monitoring with wireless internet connectivity
US6677377B2 (en) * 2000-06-21 2004-01-13 Georgetown University School Of Medicine Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6706754B2 (en) * 2000-11-06 2004-03-16 The United States Of America As Represented By The Secretary Of The Army Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
MXPA04001153A (es) * 2001-08-31 2005-02-17 Neurochem Int Ltd Derivados de amidina para tratar la amiloidosis.
AU2003302218A1 (en) 2002-05-16 2004-06-18 Genelabs Technologies, Inc Aryl and heteroaryl compounds as antibacterial and antifungal agents
MXPA04012628A (es) * 2002-06-13 2005-03-23 Patricia Olivershaffer DERIVADOS Y COMPUESTOS RELACIONADOS DEL áCIDO 2-UREIDO-6-HETEROARIL-3H-BENZOIMIDAZOL-4-CARBOXILICO COMO INHIBIDORES DE GIRASA Y/O TOPOISOMERASA IV PARA EL TRATAMIENTO DE INFECCIONES BACTERIALES.
US7582641B2 (en) * 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7618974B2 (en) * 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) * 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
WO2005089370A2 (en) 2004-03-16 2005-09-29 Goodis Charles J Endodontic files and obturator devices and methods of manufacturing same
US7459457B2 (en) 2004-04-13 2008-12-02 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7817792B2 (en) * 2006-05-04 2010-10-19 Microsoft Corporation Hyperlink-based softphone call and management
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
EP2194981B1 (de) * 2007-10-05 2011-11-23 Université de Mons-Hainaut Bisbenzimidazole und mittel gegen malaria
US8748618B2 (en) 2009-05-13 2014-06-10 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia
RU2625305C2 (ru) 2011-01-14 2017-07-13 Сперо Тринем, Инк. Твердые формы ингибитора гиразы (r)-1-этил-3-[6-фтор-5[2-(1-гидрокси-1-метил-этил) пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил] мочевины
JP6085829B2 (ja) 2011-01-14 2017-03-01 スペロ トリネム， インコーポレイテッド ピリミジンジャイレースおよびトポイソメラーゼｉｖ阻害剤
PT2663556E (pt) 2011-01-14 2014-11-27 Vertex Pharma Processo de fabrico de inibidores de girase e topoisomerase iv
EP2663558A1 (de) 2011-01-14 2013-11-20 Vertex Pharmaceuticals Incorporated Feste formen von gyrasehemmer-(r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl-}pyrimidin-5-yl-]7-(tetrahydrofuran-2-yl-)-1h-benzimidazol-2-yl-]harnstoff
WO2012177707A1 (en) 2011-06-20 2012-12-27 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
HK1248235A1 (zh) * 2015-05-15 2018-10-12 吉利德科学公司 具有作为吲哚胺2，3-二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物
EA201990395A1 (ru) 2016-07-27 2019-07-31 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Варианты комбинированной терапии для лечения рака
US20200030295A1 (en) * 2016-08-02 2020-01-30 Friedrich-Alexander-Universität Erlangen-Nürnberg Heterocyclic diamidines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1542284A (en) * 1976-01-09 1979-03-14 Barcrest Ltd Recording electrical information
ES467739A1 (es) * 1977-03-16 1979-07-01 Hoechst Ag Procedimiento para la preparacion de compuestos de bisbenci-midazolil sustituidos
DE2839989A1 (de) * 1978-09-14 1980-04-03 Hoechst Ag Substituierte bisbenzimidazolylverbindungen, ihre herstellung und ihre verwendung
US4963589A (en) * 1988-10-25 1990-10-16 The University Of North Carolina At Chapel Hill Methods for treating Giardia lamblia
US4933347A (en) * 1988-10-25 1990-06-12 University Of North Carolina At Chapel Hill Diamidines and bis(imidazolines) for the treatment of and prophylaxis against pneumocystis carinii pneumonia
US5134152A (en) * 1989-12-07 1992-07-28 Sankyo Company, Limited Oxetane derivatives and their use as anti-fungal or fungicidal agents
FR2674246B1 (fr) * 1991-03-21 1993-07-09 Roussel Uclaf Nouveaux derives de l'acide alpha-methylene 5-thiazolacetique, leur procede de preparation et les intermediaires de ce procede, leur application a titre de fongicides et les compositions les renfermant.
EP0508527A1 (de) * 1991-04-11 1992-10-14 UNIROYAL CHEMICAL COMPANY, Inc. Pyrazol-Verbindungen mit fungizider Wirkung
US5362910A (en) * 1991-10-08 1994-11-08 Nicca Chemical Co., Ltd. Germicidal and fungicidal agent and a germicidal and fungicidal method
JPH05140114A (ja) * 1991-11-22 1993-06-08 Otsuka Chem Co Ltd アゾール−１−カルボン酸エステル誘導体及び殺菌剤
US5428051A (en) * 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5667975A (en) * 1994-05-06 1997-09-16 The University Of North Carolina Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans

Also Published As

Publication number Publication date
DE69631134D1 (de) 2004-01-29
US6294565B1 (en) 2001-09-25
US5792782A (en) 1998-08-11
ES2213775T3 (es) 2004-09-01
US5972969A (en) 1999-10-26
US6017941A (en) 2000-01-25
AU5956696A (en) 1996-12-30
EP0831832B1 (de) 2003-12-17
WO1996040145A1 (en) 1996-12-19
JPH11507036A (ja) 1999-06-22
US5639755A (en) 1997-06-17
US6046226A (en) 2000-04-04
US6156779A (en) 2000-12-05
US5817686A (en) 1998-10-06
AU705261B2 (en) 1999-05-20
DE69631134T2 (de) 2004-09-02
US5643935A (en) 1997-07-01
CA2223912A1 (en) 1996-12-19
US5817687A (en) 1998-10-06
US5939440A (en) 1999-08-17
EP0831832A4 (de) 1999-07-07
EP0831832A1 (de) 1998-04-01

Similar Documents

Publication Publication Date Title
DE69631134D1 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69523074D1 (de) Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung
DE69326352D1 (de) Verfahren zur behandlung eines metallischen chirurgischen implantats.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE395928T1 (de) Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
EP0820467A4 (de) Verfahren zur behandlung von augenkrankheiten
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DK0573604T3 (da) Fremgangsmåde til behandling af osteoporosis
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69925266D1 (de) Verfahren und gerät zur behandlung von herzarhythmie
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
EP0711159A4 (de) Verfahren und zusammensetzungen zur behandlung von asthma, arthereosklerose und entzuendlichen erkrankungen unter verwendung von optisch reinem (-)-zilenton
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
EP1009421A4 (de) Verfahren und zusammenstellungen zur verbesserten wundheilung
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DE69517954D1 (de) Vorrichtung und Verfahren zur Behandlung von Abwasser mittels biologisch aktiver Holzkohle
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties